Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.54 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1204596 | 1.00 | CTSS (0.54) | CTSSCTSKPSENENCA2JAK3 | |
| SCHEMBL12189209 | 1.00 | CTSS (0.54) | CTSSCTSKPSENENCA2JAK3 | |
| SCHEMBL1204594 | 1.00 | CTSS (0.54) | CTSSCTSKPSENENCA2JAK3 | |
| SCHEMBL14779115 | 0.87 | CTSK (0.58) | CTSSCTSKPSENENCA2KDM4E | |
| SCHEMBL1655475 | 0.85 | CTSK (0.49) | CTSSCTSKPSENENCA2JAK3 | |
| SCHEMBL4476337 | 0.85 | CTSK (0.49) | CTSSCTSKPSENENCA2JAK3 | |
| SCHEMBL4476340 | 0.85 | CTSK (0.49) | CTSSCTSKPSENENCA2JAK3 | |
| SCHEMBL12878138 | 0.84 | CTSK (0.56) | CTSSCTSKPSENENCA2KDM4E | |
| SCHEMBL23990580 | 0.82 | JAK3 (0.41) | CTSSCTSKPSENENCA2JAK3 | |
| SCHEMBL8933949 | 0.82 | CTSK (0.57) | CTSSCTSKPSENENCA2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | CTSS 210/4885CTSK 174/4885PSENEN 401/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | CTSS 199/4885CTSK 307/4885PSENEN 150/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | CTSS 210/4885CTSK 174/4885PSENEN 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.